Nanobiotix Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	7.16	-11.61	30.06	-	0.01	0.05
Other Revenue	3	4.42	6.15	4.78	2.64	2.28
Revenue	10.16	-7.19	36.21	4.78	2.65	2.33
Revenue Growth (YoY)	-75.93%	-	658.12%	80.43%	13.85%	-8.50%
Gross Profit	10.16	-7.19	36.21	4.78	2.65	2.33
Selling, General & Admin	21	20.53	22.05	17.86	19.43	14.61
Research & Development	33.08	40.54	38.4	32.64	30.38	24.33
Operating Expenses	54.09	61.07	60.45	50.49	49.81	38.94
Operating Income	-43.93	-68.26	-24.24	-45.72	-47.17	-36.62
Interest Expense	-8.47	-8.09	-7.98	-5.84	-0.67	-0.33
Interest & Investment Income	1.73	2.63	1.22	0.26	-	-
Currency Exchange Gain (Loss)	-2.16	2.99	-2.09	2.11	6.24	-1.59
Other Non Operating Income (Expenses)	0	0	0	0	0.01	4.77
EBT Excluding Unusual Items	-52.82	-70.73	-33.09	-49.19	-41.58	-33.77
Gain (Loss) on Sale of Investments	-	-	-4.23	-	-	-
Other Unusual Items	1.14	2.7	-2.26	-7.84	-5.41	0.19
Pretax Income	-51.68	-68.03	-39.58	-57.03	-47	-33.58
Income Tax Expense	-0.04	0.1	0.12	0.01	0.01	0.01
Net Income	-51.64	-68.13	-39.7	-57.04	-47	-33.59
Preferred Dividends & Other Adjustments	-	-	-	-	0.06	-
Net Income to Common	-51.64	-68.13	-39.7	-57.04	-47.06	-33.59
Shares Outstanding (Basic)	47	47	37	35	35	24
Shares Outstanding (Diluted)	47	47	37	35	35	24
Shares Change (YoY)	10.33%	27.99%	5.96%	0.34%	42.43%	12.73%
EPS (Basic)	-1.09	-1.44	-1.08	-1.64	-1.35	-1.38
EPS (Diluted)	-1.09	-1.44	-1.08	-1.64	-1.35	-1.38
Free Cash Flow	-31.63	-20.4	-12.8	-37.2	-30.1	-27.63
Free Cash Flow Per Share	-0.67	-0.43	-0.35	-1.07	-0.87	-1.13
Gross Margin	100.00%	-	100.00%	100.00%	100.00%	100.00%
Operating Margin	-432.38%	-	-66.94%	-957.22%	-1781.83%	-1574.88%
Profit Margin	-508.35%	-	-109.64%	-1194.33%	-1777.97%	-1444.73%
Free Cash Flow Margin	-311.38%	-	-35.36%	-778.79%	-1137.14%	-1188.56%
EBITDA	-43.84	-67.67	-23.69	-44.22	-45.61	-34.86
EBITDA Margin	-	-	-65.42%	-	-	-
D&A For EBITDA	0.08	0.59	0.55	1.5	1.56	1.75
EBIT	-43.93	-68.26	-24.24	-45.72	-47.17	-36.62
EBIT Margin	-	-	-66.94%	-	-	-
Revenue as Reported	10.16	-7.19	36.21	4.78	2.65	2.51

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q